{
    "clinical_study": {
        "@rank": "13466", 
        "acronym": "LaRCA", 
        "arm_group": [
            {
                "arm_group_label": "Specific Lp(a) apheresis & Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Specific Lp(a) apheresis was performed with \"Lp(a) Lipopak\" immunosorbent columns (\"POCARD\" Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "No Intervention", 
                "description": "Standard medical therapy in accordance with the recommendations for secondary prevention of CHD"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy\n      could affect atherosclerotic disease burden in coronary and carotid arteries of coronary\n      heart disease  patients with elevated Lp(a) levels."
        }, 
        "brief_title": "Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Atherosclerosis", 
            "Coronary Disease", 
            "Carotid Artery Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Carotid Artery Diseases", 
                "Coronary Disease", 
                "Coronary Artery Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Following the hypothesis that if Lp(a) excess has a pathogenic role in atherogenesis, then\n      specific elimination of circulating Lp(a) should affect plaque growth and stability, we\n      evaluated the efficacy of Lp(a) apheresis on changes in coronary plaque volume and\n      composition and carotid intima-media thickness in patients with CHD on the background of\n      optimal medical treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable coronary heart disease (CHD) requiring a clinically indicated coronary\n             angiography.\n\n          -  Lp(a) \u226550 mg/dL\n\n          -  LDL-C <2.6 mmol/L (100 mg/dL)\n\n          -  Signed written informed consent form to participate in the study\n\n        Exclusion Criteria:\n\n          -  history of acute coronary syndrome or surgical intervention within prior 3 months to\n             inclusion\n\n          -  chronic infectious and inflammatory diseases\n\n          -  familial hypercholesterolemia\n\n          -  TG \u22654.5 mmol/L (400 mg/dL)\n\n          -  Active liver disease (ALT or AST >3 upper limit of normal (ULN), or total bilirubin\n             >1.5 ULN);\n\n          -  CK \u22653 ULN;\n\n          -  Thyroid dysfunction;\n\n          -  Renal dysfunction (creatinine clearance (Cockcroft-Gault Equation) \u226430 ml/min);\n\n          -  Uncontrolled diabetes (HbA1c \u22657.0%);\n\n          -  Coagulopathies;\n\n          -  Lipid-lowering drugs, except statins for the last month\n\n          -  Known statin or immunoadsorption intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133807", 
            "org_study_id": "01200953720"
        }, 
        "intervention": {
            "arm_group_label": "Specific Lp(a) apheresis & Atorvastatin", 
            "description": "Specific Lp(a) apheresis procedures were carried out weekly with \"Lp(a) Lipopak\" columns (POCARD Ltd., Moscow, Russia) according to the standard protocol", 
            "intervention_name": "Specific Lp(a) apheresis", 
            "intervention_type": "Procedure", 
            "other_name": "\"Lp(a) Lipopak\" immunoadsorption columns"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lipoprotein(a);", 
            "Lp(a) immunoadsorption;", 
            "Apheresis;", 
            "Coronary atherosclerosis;", 
            "Carotid Atherosclerosis;", 
            "Intima-media thickness;", 
            "Regression;", 
            "Quantitative Coronary Angiography;", 
            "Intravascular Ultrasound;", 
            "Virtual Histology;", 
            "Plaque;", 
            "Atorvastatin;"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "121552"
                }, 
                "name": "Russian Cardiology Research and Production Center"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level.", 
        "other_outcome": [
            {
                "description": "Mean changes in TC level over the 18-month study period", 
                "measure": "Total Cholesterol (TC) Serum Level", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "description": "Mean changes in Lp(a) level over the 18-month study period", 
                "measure": "Lipoprotein(a) (Lp(a)) serum levels", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "description": "Mean changes in LDL-C level over the 18-month study period", 
                "measure": "Low-density lipoprotein cholesterol (LDL-C) serum Level", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "description": "Since all included patients had high Lp(a) levels, to avoid overestimation of LDL-C fraction estimated LDL-C levels were corrected for cholesterol derived from Lp(a).\nCorrected LDL-C (LDL-C corr) was calculated using Dahlen's modification of the Friedewald formula: LDL-C corr = TC - (HDL-C) - (TG / 2.2) - (0.3 x Lp(a) / 38.7).\nFor values in mmol/L, Lp(a) in mg/dL", 
                "measure": "Change in corrected LDL-C (LDL-C corr) Serum level", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "description": "Mean changes in TG level over the 18-month study period", 
                "measure": "Change in triglycerides (TG) serum Level", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "description": "Mean changes in HDL-C level over the 18-month study period", 
                "measure": "Change in high-density lipoprotein cholesterol (HDL-C) serum level", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "measure": "Change in hemoglobin level", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "measure": "Change in creatinine level", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "measure": "Change in creatine kinase (CK) level", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "measure": "Change in alanine transaminase (ALT) level", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }, 
            {
                "measure": "Change in aspartate transaminase (AST) level", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to Week 4, 36, 72"
            }
        ], 
        "overall_official": {
            "affiliation": "Russian Cardiology Research and Production Center", 
            "last_name": "Sergei Pokrovsky, PhD, DSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The absolute change from baseline to 18 months in mean percent diameter stenosis, determined by quantitative coronary angiography (QCA) as the narrowest lesion in each segment and calculated as: ((reference diameter-minimal lumen diameter (MLD))/reference diameter)x100.", 
            "measure": "Change in Percent Diameter Stenosis", 
            "safety_issue": "No", 
            "time_frame": "From Baseline to End of Study (Week 72)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133807"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Russian Cardiology Research and Production Center", 
            "investigator_full_name": "Professor Sergei Pokrovsky, PhD, DSc", 
            "investigator_title": "Chair of the Laboratory of Atherosclerosis", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in mean carotid IMT, as measured by duplex ultrasonography of common carotid arteries after 9 and 18 months.", 
                "measure": "Change  in mean carotid intima-media thickness (IMT)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 36 (9 months) and to Week 72 (18 months)"
            }, 
            {
                "description": "Clinically relevant regression or progression was defined as a change from baseline to follow up of \u226510% for percent diameter stenosis", 
                "measure": "Numbers of Coronary segments Showing Regression", 
                "safety_issue": "No", 
                "time_frame": "From baseline to End of study (Week 72)"
            }, 
            {
                "description": "Carotid IMT progression criterion for the 18 months of treatment was considered as growth rate of 0.02 mm (0.015 mm/yr). No changes or reduction in carotid IMT \u2265 0,02 mm served as criterion of stabilization and regression of carotid atherosclerosis, respectively.", 
                "measure": "Number of Carotid Segments showing Regression", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to End of study (Week 72)"
            }, 
            {
                "description": "TAV at baseline - TAV at Week 72 assessed by intravascular ultrasound (IVUS) imaging of a targeted coronary artery", 
                "measure": "Change in total atheroma volume (TAV) from baseline to 18 months post-therapy", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 72"
            }, 
            {
                "description": "Mean change in absolute volumes of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy", 
                "measure": "Change in absolute volumes of plaque components", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to  Week 72"
            }, 
            {
                "description": "Mean change in relative amounts of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy", 
                "measure": "Change in relative amount of plaque components", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 72"
            }, 
            {
                "description": "Regression was defined as decrease in TAV for all anatomically comparable cross sectional areas of targeted coronary artery from baseline of \u2265 0,1 mm cubed", 
                "measure": "Numbers of Coronary Plaques Showing Regression", 
                "safety_issue": "No", 
                "time_frame": "From baseline to End of study (Week 72)"
            }, 
            {
                "description": "Difference in Lp(a) concentration before and after specific Lp(a) apheresis procedure calculated as the mean of all measurements", 
                "measure": "Acute change in Lp(a) level", 
                "safety_issue": "No", 
                "time_frame": "Once a week over 72 week period of active treatment"
            }, 
            {
                "description": "To evaluate the impact of the specific Lp(a) removal therapy on the quality of life using Seattle Angina Questionnaire (SAQ) and Exercise stress test as compared with standard guideline-driven medical therapy of CHD patients", 
                "measure": "Change in quality of life (QOL)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to week 72"
            }
        ], 
        "source": "Russian Cardiology Research and Production Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Clinical Diagnostic Center MEDSI", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Moscow State Government", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Russian Cardiology Research and Production Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}